Clinico‐genetic spectrum of limb‐girdle muscular weakness in Austria: A multicentre cohort study. (10th March 2022)

• Record Type: Journal Article
• Authors: Krenn, Martin; Tomschik, Matthias; Wagner, Matias; Zulehner, Gudrun; Weng, Rosa; Rath, Jakob; Klotz, Sigrid; Gelpi, Ellen; Bsteh, Gabriel; Keritam, Omar; Colonna, Isabella; Paternostro, Chiara; Jäger, Fiona; Lindeck‐Pozza, Elisabeth; Iglseder, Stephan; Grinzinger, Susanne; Schönfelder, Martina; Hohenwarter, Christina; Freimüller, Manfred; Embacher, Norbert; Wanschitz, Julia; Topakian, Raffi; Töpf, Ana; Straub, Volker; Quasthoff, Stefan; Zimprich, Fritz; Löscher, Wolfgang N.; Cetin, Hakan
• Is Part Of: European journal of neurology. Volume 29:Number 6(2022)
• Page Start: 1815
• Page End: 1824
• Publication Date: 2022-03-10
• Subjects: Austria -- limb‐girdle muscular dystrophy -- limb‐girdle muscular weakness -- myopathy -- next‐generation sequencing; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.15306
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract: Background and purpose: Hereditary myopathies with limb‐girdle muscular weakness (LGW) are a genetically heterogeneous group of disorders, in which molecular diagnosis remains challenging. Our aim was to present a detailed clinical and genetic characterization of a large cohort of patients with LGW. Methods: This nationwide cohort study included patients with LGW suspected to be associated with hereditary myopathies. Parameters associated with specific genetic aetiologies were evaluated, and we further assessed how they predicted the detection of causative variants by conducting genetic analyses. Results: Molecular diagnoses were identified in 62.0% (75/121) of the cohort, with a higher proportion of patients diagnosed by next‐generation sequencing (NGS) than by single‐gene testing (77.3% vs. 22.7% of solved cases). The median (interquartile range) time from onset to genetic diagnosis was 8.9 (3.7–19.9) and 17.8 (7.9–27.8) years for single‐gene testing and NGS, respectively. The most common diagnoses were myopathies associated with variants in CAPN3 ( n = 9), FKRP ( n = 9), ANO5 ( n = 8), DYSF ( n = 8) and SGCA ( n = 5), which together accounted for 32.2% of the cohort. Younger age at disease onset ( p = 0.043), >10× elevated creatine kinase activity levels ( p = 0.024) and myopathic electromyography findings ( p = 0.007) were significantly associated with the detection of causative variants. Conclusions: Our findings suggest that an earlier use of NGS in patients with LGW is needed to avoid long diagnostic delays. We further present parameters predictive of a molecular diagnosis that may help to select patients for genetic analyses, especially in centres with limited access to sequencing. Abstract : We provide a nationwide characterization of Austrian patients with limb‐girdle weakness. A molecular diagnosis was found in 62%, with CAPN3, FKRP, ANO5, DYSF and SGCA representing the five most common subtypes. Our data suggest an earlier use of NGS is needed to avoid diagnostic delays.